Effects of janus-kinase inhibitor therapy on lipid parameters in patients with IBD

被引：0
|
作者：
Prabhu, A. [1 ]
Al Dehailan, R. [1 ]
Azzu, H. [1 ]
Sanford, J. [1 ]
Cripps, S. [1 ]
Scaria, L. [1 ]
Walsh, A. [1 ]
机构：
[1] Oxford Univ Hosp NHS Fdn Trust, Translat Gastroenterol Unit, Oxford, England
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
RHEUMATOID-ARTHRITIS;
D O I：
10.1093/ecco-jcc/jjae190.1335
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1161
引用
收藏
页码：i2123 / i2123
页数：1
相关论文
共 50 条
  • [1] Intracerebral bleeding after Janus-kinase inhibitor baricitinib for COVID-19
    Finsterer, Josef
    Scorza, Fulvio A.
    BRAIN HEMORRHAGES, 2021, 2 (04): : 151 - 152
  • [2] Success for a new Generation of Basic Therapeutics The Janus-Kinase -Inhibitor Baricitinib in rheumatoid Arthritis
    Keysser, G.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2017, 76 (05): : 461 - 462
  • [3] Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions
    Fukuyama, Tomoki
    Tschernig, Thomas
    Qi, Yulin
    Volmer, Dietrich A.
    Baeumer, Wolfgang
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 764 : 278 - 282
  • [4] The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
    Andreas Neubauer
    Johannes Johow
    Elisabeth Mack
    Andreas Burchert
    Damaris Meyn
    Andrea Kadlubiec
    Iuliu Torje
    Hinnerk Wulf
    Claus F. Vogelmeier
    Joachim Hoyer
    Chrysanthi Skevaki
    Ralf Michael Muellenbach
    Christian Keller
    Carmen Schade-Brittinger
    Caroline Rolfes
    Thomas Wiesmann
    Leukemia, 2021, 35 : 2917 - 2923
  • [5] Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review
    Challoumas, Dimitris
    Simpson, Cameron
    Arnold, Matthew
    Mease, Philip
    Moots, Robert
    Ndosi, Mwidimi
    Locher, Zoe Rutter
    AUTOIMMUNITY REVIEWS, 2025, 24 (03)
  • [6] Janus Kinase Inhibitor Therapy in Patients with Multiple Sclerosis and Co-Morbid Conditions
    Pua, Danielle Kei
    Madill, Evan
    Bhattacharyya, Shamik
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1016 - 1016
  • [7] Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis
    Huang, Baozhen
    Wang, Xinning
    Niu, Yanlin
    Ding, Yuchuan
    Wang, Xiaolei
    Tan, Qingqing
    Li, Yucong
    Liu, Yuan
    Chi, Ying
    Wang, Yuan
    Zhou, Zhixuan
    Li, Jianguo
    RHEUMATOLOGY, 2023, 62 (03) : 1227 - 1237
  • [8] Practical management of patients on Janus kinase inhibitor (JAKi) therapy - the CRI fact sheets
    Richez, Christophe
    Morel, Jacques
    Sibilia, Jean
    Pham, Thao
    JOINT BONE SPINE, 2019, 86 : ES1 - ES1
  • [9] Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib - A report of two cases
    Wendel, Sarah
    Venhoff, Nils
    Frye, Bjoern C.
    May, Annette M.
    Agarwal, Prerana
    Rizzi, Marta
    Voll, Reinhard E.
    Thiel, Jens
    JOURNAL OF AUTOIMMUNITY, 2019, 100 : 131 - 136
  • [10] Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor
    Nasifoglu, S.
    Heinrich, B.
    Welzel, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (02) : 504 - 505
12345